Cargando…
The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting
SIMPLE SUMMARY: In this monocentric retrospective analysis, the extent of resection of singular/solitary brain metastases has no impact on local recurrence and overall survival rates in patients receiving multidisciplinary adjuvant treatment. Since systemic disease progression is the leading cause o...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004079/ https://www.ncbi.nlm.nih.gov/pubmed/33801110 http://dx.doi.org/10.3390/cancers13061435 |
_version_ | 1783671840558809088 |
---|---|
author | Jünger, Stephanie T. Pennig, Lenhard Schödel, Petra Goldbrunner, Roland Friker, Lea Kocher, Martin Proescholdt, Martin Grau, Stefan |
author_facet | Jünger, Stephanie T. Pennig, Lenhard Schödel, Petra Goldbrunner, Roland Friker, Lea Kocher, Martin Proescholdt, Martin Grau, Stefan |
author_sort | Jünger, Stephanie T. |
collection | PubMed |
description | SIMPLE SUMMARY: In this monocentric retrospective analysis, the extent of resection of singular/solitary brain metastases has no impact on local recurrence and overall survival rates in patients receiving multidisciplinary adjuvant treatment. Since systemic disease progression is the leading cause of death, and an uncontrolled systemic disease status, along with adjuvant treatment, present independent predictors of overall survival, a comprehensive, multidisciplinary treatment concept is essential for patients with brain metastases. ABSTRACT: Background and Purpose: The value of gross-total surgical resection remains debatable in patients with brain metastases (BMs) as most patients succumb to systemic disease progression. In this study, we evaluated the impact of the extent of resection of singular/solitary BM on in-brain recurrence (iBR), focusing on local recurrence (LR) and overall survival (OS) in an interdisciplinary adjuvant treatment setting. Patients and Methods: In this monocentric retrospective analysis, we included patients receiving surgery of one BM and subsequent adjuvant treatment. A radiologist and a neurosurgeon determined in consensus the extent of resection based on magnetic resonance imaging. The OS was calculated using Kaplan–Meier estimates; prognostic factors for LR and OS were analysed by Log rank test and Cox proportional hazards. Results: We analyzed 197 patients. Gross-total resection was achieved in 123 (62.4%) patients. All patients were treated with adjuvant radiotherapy, and 130 (66.0%) received systemic treatment. Ninety-six (48.7%) patients showed iBR with an LR rate of 23.4%. LR was not significantly influenced by the extent of resection (p = 0.139) or any other parameter. The median OS after surgery was 18 (95%CI 12.5–23.5) months. In univariate analysis, the extent of resection did not influence OS (p = 0.6759), as opposed to adjuvant systemic treatment (p < 0.0001) and controlled systemic disease (p = 0.039). Systemic treatment and controlled disease status remained independent factors for OS (p < 0.0001 and p = 0.009, respectively). Conclusions: In this study, the extent of resection of BMs neither influenced the LR nor the OS of patients receiving interdisciplinary adjuvant treatment. |
format | Online Article Text |
id | pubmed-8004079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80040792021-03-28 The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting Jünger, Stephanie T. Pennig, Lenhard Schödel, Petra Goldbrunner, Roland Friker, Lea Kocher, Martin Proescholdt, Martin Grau, Stefan Cancers (Basel) Article SIMPLE SUMMARY: In this monocentric retrospective analysis, the extent of resection of singular/solitary brain metastases has no impact on local recurrence and overall survival rates in patients receiving multidisciplinary adjuvant treatment. Since systemic disease progression is the leading cause of death, and an uncontrolled systemic disease status, along with adjuvant treatment, present independent predictors of overall survival, a comprehensive, multidisciplinary treatment concept is essential for patients with brain metastases. ABSTRACT: Background and Purpose: The value of gross-total surgical resection remains debatable in patients with brain metastases (BMs) as most patients succumb to systemic disease progression. In this study, we evaluated the impact of the extent of resection of singular/solitary BM on in-brain recurrence (iBR), focusing on local recurrence (LR) and overall survival (OS) in an interdisciplinary adjuvant treatment setting. Patients and Methods: In this monocentric retrospective analysis, we included patients receiving surgery of one BM and subsequent adjuvant treatment. A radiologist and a neurosurgeon determined in consensus the extent of resection based on magnetic resonance imaging. The OS was calculated using Kaplan–Meier estimates; prognostic factors for LR and OS were analysed by Log rank test and Cox proportional hazards. Results: We analyzed 197 patients. Gross-total resection was achieved in 123 (62.4%) patients. All patients were treated with adjuvant radiotherapy, and 130 (66.0%) received systemic treatment. Ninety-six (48.7%) patients showed iBR with an LR rate of 23.4%. LR was not significantly influenced by the extent of resection (p = 0.139) or any other parameter. The median OS after surgery was 18 (95%CI 12.5–23.5) months. In univariate analysis, the extent of resection did not influence OS (p = 0.6759), as opposed to adjuvant systemic treatment (p < 0.0001) and controlled systemic disease (p = 0.039). Systemic treatment and controlled disease status remained independent factors for OS (p < 0.0001 and p = 0.009, respectively). Conclusions: In this study, the extent of resection of BMs neither influenced the LR nor the OS of patients receiving interdisciplinary adjuvant treatment. MDPI 2021-03-21 /pmc/articles/PMC8004079/ /pubmed/33801110 http://dx.doi.org/10.3390/cancers13061435 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jünger, Stephanie T. Pennig, Lenhard Schödel, Petra Goldbrunner, Roland Friker, Lea Kocher, Martin Proescholdt, Martin Grau, Stefan The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting |
title | The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting |
title_full | The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting |
title_fullStr | The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting |
title_full_unstemmed | The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting |
title_short | The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting |
title_sort | debatable benefit of gross-total resection of brain metastases in a comprehensive treatment setting |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004079/ https://www.ncbi.nlm.nih.gov/pubmed/33801110 http://dx.doi.org/10.3390/cancers13061435 |
work_keys_str_mv | AT jungerstephaniet thedebatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting AT penniglenhard thedebatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting AT schodelpetra thedebatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting AT goldbrunnerroland thedebatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting AT frikerlea thedebatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting AT kochermartin thedebatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting AT proescholdtmartin thedebatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting AT graustefan thedebatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting AT jungerstephaniet debatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting AT penniglenhard debatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting AT schodelpetra debatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting AT goldbrunnerroland debatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting AT frikerlea debatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting AT kochermartin debatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting AT proescholdtmartin debatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting AT graustefan debatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting |